All In Biotech

Drug Trial Radar · NCT00128323

A Comparison of Gentian Violet (GV) Mouth Washes, Nystatin, and Ketoconazole Tabs in Treating Oropharyngeal Candidiasis

A Comparison of Gentian Violet Mouth Washes, Nystatin Drops and Ketoconazole Tabs in the Treatment of Oropharyngeal Candidiasis

Last checked: Nov 19, 2026Latest source record: Feb 11, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 558 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

558

Actual

Start

Nov 2002

Primary completion

Not stated

Study completion Apr 2005

Sponsor

Lead sponsor
Kamuzu University of Health SciencesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
British Society for Antimicrobial Chemotherapy
First posted
Aug 9, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, up to 14 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In resource constrained societies and where HIV is a problem, oral thrush causes significant morbidity. In adults, ketoconazole is used and sometimes oral nystatin. Both drugs are relatively expensive compared to GV solution and ketoconazole has significant side effects especially in association with some of the treatments for HIV related problems. In children, either GV solutions or nystatin are used, GV is a fraction of the cost of nystatin. GV at 1% solution discolours the mouth (blue) and in the older child and adult would mark them out as having HIV infections. A much more dilute solution of GV has proved equally effective in vitro and would not carry the same cosmetic problem. In this study of children, the investigators have compared the 3 solutions, 1% GV, 0.00165% GV and nystatin oral drops - all masked so that they look the same - to see if GV is more effective than nystatin, and to see if the weaker solution of GV is as effective as the stronger solution.

Conditions

  • Candidiasis, Oral

Interventions

  • Gentian violet 1% solutionDrug

  • Gentian violet 0.00165% solutionDrug

  • Nystatin solutionDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical clearance of oral candidiasis by day 12
  2. Fungal clearance of oral candidiasis by saliva culture

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Queen Elizabeth Central Hospital, Paediatric Dept, Box 360

    Blantyre, Malawi

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.